Oncology and Radiotherapy ©
Vol.17 Iss.12: 756-763 • REVIEW ARTICLE

Theranostics in Nuclear Medicine: Therapy to Impact Patient Management and Secure the Future in the era of precision oncology

Sachin Pradhan, Chetan Kumar Sonkar

Department of Pharmacy, Kalinga University, Naya Raipur, Chhattisgarh, India

Abstract

Precision oncology has become a revolutionary strategy in cancer treatment, providing personalized patient care by considering their unique genetic, molecular, and clinical attributes. The technique has significantly reshaped the cancer detection and therapy domain, emphasizing the pivotal significance of Theranostics in Nuclear Medicine (TNM). The integration of diagnostics and therapeutics in TNM represents a significant advancement in nuclear medicine imaging since it enables the implementation of tailored medicines for the precise management of tumors. The relevance of this approach is in its ability to provide patients with individualized treatment programs via the identification of particular molecular targets, therefore reducing the occurrence of side effects and improving therapeutic results. Although the advantages of using the TNM system in precision oncology are indisputable, some obstacles must be addressed. The presence of heterogeneity among cancer cells, coupled with the inherent constraints of targeted treatment, necessitates the development of new alternatives. Recent developments in the field of TNM have shown encouraging results, including the use of Lutetium therapy for the treatment of prostate cancer, Yttrium-90 SIRT therapy for liver cancer, and Iodine-131 therapy for thyroid diseases. The medicines have shown noteworthy outcomes, emphasizing the potential of TNM in enhancing healthcare provision to patients. The experimental findings provide further evidence supporting the effectiveness of TNM, as demonstrated by significant improvements in key metrics such as signal-to-noise ratio, contrast-to-noise ratio, Image Spatial Resolution, and Lesion Detection Sensitivity. The results support the use of TNM as a crucial instrument in improving patient care and safety by administering focused medication while minimizing adverse effects.

Key Words: precision oncology, theranostics, nuclear medicine, patient management.

Address for correspondence
Sachin Pradhan, Department of Pharmacy, Kalinga University, Naya Raipur, Chhattisgarh, India, Email: ku.sachinpradhan@kalingauniversity.ac.in

Word count: 4385 **Tables:** 00 **Figures:** 07 **References:** 16

Received:-28 October, 2023, Manuscript No. OAR-23-122991
Editor assigned:- 01 November, 2023, Pre-QC No. OAR-23-122991 (PQ)
Reviewed:- 08 November, 2023, QC No. OAR-23-122991 (Q)
Revised:- 21 November, 2023, Manuscript No. OAR-23-122991 (R)
Published:- 29 November, 2023, Invoice No. J-122991

INTRODUCTION TO PRECISION ONCOLOGY AND THERANOSTICS

Precision Oncology is an innovative strategy for cancer management that involves the individualized adaptation of treatments according to an individual patient's unique genetic, molecular, and clinical characteristics [1]. The paradigm shift is a departure from the conventional approach of using a uniform treatment plan for all patients and offers a new and transformative age in the field of cancer care. Tailored patient treatment and security is a fundamental tenet of precision oncology [2]. As the research explores the field of precision oncology, it becomes apparent that the integration of individualized patient data and new medical technology has the promise of transforming the approach to cancer therapy [3].

Patient care is given utmost priority in Precision Oncology [4]. Healthcare practitioners can optimize therapeutic strategies by using individualized treatment options that consider the distinct features of an individual patient's cancer. The comprehensive methodology considers many factors, including the specific classification of cancer, its stage of progression, its genetic characteristics, and the general state of health [5]. The outcome encompasses not only an enhanced probability of treatment efficacy, as seen by augmented five-year survival rates, but also a treatment regimen that is more accommodating to the needs and preferences of patients. The emphasis on patient safety is inherent to the precision oncology paradigm since it reduces the likelihood of adverse reactions by explicitly targeting the illness and safeguarding unaffected tissues [6].

The constraints of traditional cancer therapies emphasize the need for precision oncology therapy [7]. The effectiveness of standard treatments, like chemotherapy and radiation therapy, might vary due to genetic inequalities across individuals and intra-tumoral heterogeneity. Precision oncology has emerged as a promising approach to address the difficulty of cancer therapy customization [8]. This approach involves the adaptation of treatment regimens according to the unique genetic alterations detected in a patient's tumor. Precision oncology aims to achieve a more accurate and efficient response to cancer [9]. Using a personalized treatment strategy for patients demonstrates a significant increase in favorable response rates, sometimes exceeding the established threshold of 70%. In addition to the observed increase in response rates, precision oncology therapy offers significant advantages in improving the patient's quality of life during treatment [10]. By selectively eradicating malignant cells while safeguarding normal tissue, this approach mitigates the adverse effects often seen in conventional therapies, enhancing patient quality of life and enabling the pursuit of more intensive treatment strategies.

However, the field of precision oncology is full of challenges. The presence of diverse genetic variants inside a single tumor is a significant obstacle, requiring a personalized strategy for each patient in the context of cancer. The discovery of relevant genetic biomarkers poses an additional challenge since determining the most significant mutations for making treatment choices requires thorough investigation and comprehensive data processing. The effective administration of the complex network of genetic data is an additional challenge in precision oncology. The analysis and interpretation of vast amounts of genomic data necessitates using sophisticated computer techniques and specialized knowledge. The prominence of ethical considerations about data security and patient confidentiality becomes apparent, given the substantial reliance of precision oncology on comprehensive patient data for research and therapeutic decision-making. The constant challenge in this pioneering subject is to achieve a healthy balance between data security and research objectives.

The main contributions are listed below:

- Theranostics is an integrated technique that merges the fields of therapeutics and diagnostics, resulting in a comprehensive and efficient method that encompasses both diagnosis and treatment inside a single entity. This approach is known for its cost-effectiveness and time-saving benefits.
- Some notable advancements in the field of personalized medicine include the utilization of Lutetium PSMA therapy for the treatment of metastatic prostate cancer, Yttrium-90 SIRT therapy for liver cancer, and Iodine-131 therapy for thyrotoxicosis and thyroid cancer.
- The development of emerging theranostic agents such as Lu-Pentixather and I-Metomidate has shown encouraging outcomes in effectively targeting specific receptors and enhancing the effectiveness of treatment in different forms of cancer.

The following sections are arranged in the following manner: Section 2 provides an overview of the current body of literature and research on theranostics within the nuclear medicine domain. Section 3 introduces the notion of Theranostics in Nuclear Medicine (TNM) and explores its possible applications in customized cancer therapy. Section 4 provides a comprehensive examination of the experimental analysis and results of the use of theranostics within the field of nuclear medicine. Section 5 presents a complete conclusion and delves into the potential future advancements of theranostics in nuclear medicine.

LITERATURE SUMMARY

This section thoroughly examines the extant corpus of scholarly research and investigations about theranostics in nuclear medicine, offering a detailed synopsis of the present condition of the discipline. The current work contextualizes its contribution by illustrating its position within the broader domain of theranostics research and the progress it builds upon.

The study conducted by Konijnenberg et al. offers valuable insights into the adherence to nuclear medicine treatment by Council Directive Euratom [11]. The study underscores the significance of ensuring radiation safety. This article presents a set of recommendations aimed at enhancing patient safety within the field of nuclear medicine. The guidelines focus on two key aspects: dose optimization and tailored therapy. These measures are paramount in ensuring nuclear medicine procedures' safe and effective delivery.

Sollini et al. provide a comprehensive atlas that uses nuclear medicine imaging techniques to diagnose and evaluate lung infections [12]. By presenting diverse case-based situations, the authors effectively illustrate the importance of radiopharmaceuticals in diagnosing and monitoring lung infections. This provides valuable perspectives on utilizing nuclear imaging techniques in infectious illnesses.

Dukart et al. provide JuSpace, a novel tool for spatial correlation analysis between Magnetic Resonance Imaging (MRI) data and neurotransmitter maps produced from nuclear imaging techniques [13]. This unknown program enables the amalgamation of structural and functional neuroimaging data, significantly contributing to neuroimaging research and its use in the mental health field.

Fu et al. provide a comprehensive and contemporary analysis of nuclear molecular imaging techniques to detect and characterize thyroid tumors [14]. The study discusses the most recent progressions in nuclear imaging methodologies for diagnosing and treating thyroid cancer. They specifically emphasize the significance of radiotracers in identifying and characterizing malignant thyroid tumors, contributing to a more comprehensive comprehension of this particular domain.

Arnon-Sheleg et al. explore the imaging domain for vascular graft infection, considered a crucial area in nuclear medicine [15]. The work offers valuable perspectives on various imaging modalities and procedures, emphasizing the need for timely and precise detection. It highlights the use of nuclear imaging as a diagnostic tool within this particular context.

Fanti et al. comprehensively analyze consensus statements about the evaluation criteria for Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography/Computed Tomography (PET/CT) response in prostate cancer [16]. The present study aims to provide a standardized approach for evaluating prostate cancer via the use of PSMA PET/CT. This standardized assessment method is expected to facilitate consistent interpretation of data and improve the overall precision of this particular imaging modality.

Sanaat et al. provide a novel approach to whole-body PET/CT imaging incorporating deep learning techniques to achieve enhanced speed and reduced radiation dosage [17]. Their study's primary area of investigation pertains to using deep learning algorithms to facilitate expedited and low-dose PET/CT scans. This innovation has the potential to significantly transform imaging protocols by mitigating radiation exposure and decreasing the duration of scan procedures. Slart et al. examine PET scanners' practical use and prospective benefits with an extended axial field of view [18]. These technologies can expand the scope of nuclear imaging, enabling broader anatomical coverage and more thorough imaging, enhancing the field's capabilities.

This section identified notable obstacles within the nuclear medicine field, including ensuring radiation safety, establishing standardized criteria for assessing responses, improving imaging efficiency while minimizing radiation exposure, and incorporating improved designs for PET scanners. The suggested methodology aims to tackle these problems by providing a complete framework that enhances patient safety, standardizes evaluations, expedites imaging, and utilizes new technologies to improve diagnostic accuracy.

PROPOSED THERANOSTICS IN NUCLEAR MEDICINE

The present work introduces a novel approach that incorporates sophisticated deep learning algorithms to optimize efficiency and minimize the levels of radiation exposure in whole-body PET/CT imaging. The primary objective of this novel methodology is to enhance the precision of diagnoses while concurrently enhancing the safety of patients. Using different techniques presents a new avenue for advancing nuclear medicine, in line with the need for more effective low-radiation imaging methods.

Theranostics is a neologism derived from the fusion of "therapeutics" and "diagnostics." This pertains to a burgeoning domain of medicine whereby a mix of medications and methods is used for therapeutic and remedial purposes. This innovation represents a significant advancement since it combines diagnostic and therapeutic capabilities into a single entity. This approach offers both economic benefits and time efficiency. PET scans target tumor receptors that are found inside tumor cells specifically. If the condition is detected inside the cellular structure, a pharmacological agent with radioactive properties is used for therapeutic purposes. There are limited clinical studies about the use of therapeutics in prostate cancer, the Therapeutic Products Agency, or TGA (Figure 1).



Fig.1. Use of therapeutics in prostate cancer.

3.1 Theranostics

Nuclear medicine imaging, often known as atomic imaging, is a medical diagnostic technique that utilizes radioactive substances to see and assess the functioning of various organs and tissues inside the human field of Nuclear Medicine Imaging has been significantly transformed with the use of theranostics, which combines targeted therapeutic interventions with companion diagnostic methods to enable precise molecular localization. The system offers an individualized therapy strategy for patients by focusing on specific objectives. Several departments within the field of nuclear research may use theranostic agents.

3.2 Therapeutic bullets

Theranostics utilizes the distinctive biochemical processes inherent to various systems within the human body to get diagnostic pictures. These pictures increase the likelihood of achieving a targeted therapeutic irradiation dose, explicitly targeting the diseased area while preserving the healthy tissues.

3.3 Nuclear Medicine Imaging

Over the last century, a comparable model for neuroendocrine cancers has been established using radioactive gallium-68. The PET radioactive material in question has been chemically bound to octreotide and used in detecting tumors, exhibiting a greater degree of selectivity when compared to methods of imaging using Indium-111 octreotide.

Identifying patients' diseases is accomplished by using gallium-68, which targets the substance called receptor size and is visualized using a hybrid scanning technique such as PET-CT. The element lute Octreotate Treatment, a radioactive substance that produces beta irradiation, is now offered at five medical facilities in North America and many European healthcare facilities.

The diversity of tumor cells is a challenge for using theranostics-targeted therapies in fighting cancer. Ibritumomab, a monoclonal antibody, is used for detecting B-cells and producing a beta/alpha-emitting radiometal, which aims to eradicate lymphoma. Scanning is used to validate the spatial distribution of antibodies throughout the human body. Using indium-111 in conjunction with the radioisotope yttrium-90 facilitates the transportation of beta fragments, which are employed to eliminate B-cells (Figure 2).



Fig.2. Theragnostic in targeting and treatment.

3.4 Emerging theranostic agents

3.4.1 Lu-Pentixather

Mesenchymal or marrow-derived cells called stromal cells exhibit a continuous secretion of the chemokine stromal cell-derived factor-1. This chemokine facilitates the attraction of cancerous cells by interacting with its corresponding receptor. The cell-surface protein is known to have significant involvement in several processes, such as carcinogenesis, chemotaxis, and movement of metastatic cancerous cells. Current research has been primarily directed towards investigating the axis, with specific attention given to the approval by the Food and small-molecule blocker known as Plerixafor, which has been used for stem cell migration. In a manner akin to plerixafor, the blocker balixafortide has shown promising outcomes when administered with eribulin therapy in individuals afflicted with extensively treated, recurrent cancer of the breast.

The relationship has been extrapolated in molecular visualization to facilitate the development of radioisotope-labeled conjugates. The cyclical pentapeptide Ga-ventilator has been used for this purpose. The imaging agent has been subject to the most comprehensive investigations as a radioligand. The theranostic counterpart, Pentax-ather, has been investigated using Lu or Y radiolabeling.

To optimize the eradication of tumor cells in the bone marrow, the administration of Lu Pentax-ather by endoradiotherapy has been used in conjunction with a traditional chemotherapeutic and precondition protocol before unilateral or heterologous stem cell transplants. The research investigation documented absorbed cancer treatments ranging from 30 to 70 Gy in intra- or extramedullary tumors in patients with multiple myeloma.

3.4.2 I-Metomidate

Adrenocortical cancer, while uncommon, has a high level of aggressiveness, with an annual incidence ranging from 0.7 to 2.0 instances per 1 million individuals. In the context of a feasibility test, a cohort of 11 individuals diagnosed with nonresectable adrenocortical carcinoma who exhibited satisfactory uptake on I-etomidate SPECT was subjected to a collective sum of 19 treatment sessions. These cycles included the administration of I-etomidate, ranging from 1.6 to 20 GBq each cycle, with each patient undergoing 1 to 3 bikes. A prevalence of bone marrow transplantation depression, which was transitory, was seen in a maximum of 11% of the patient population. The best recovery in the study population was categorized as an incomplete response in one instance, stable illness in ten patients, and progressing disease in the other individuals. Among ten individuals who exhibited controlled conditions, the average survival time was 13 months, ranging from 0.35 to 33 months. However, it is essential to note that etomidate undergoes fast inactivation by endogenous esterases, potentially hindering diagnostic accuracy and treatment effectiveness. The study has proposed a new theranostic pair, azetidinylamide, which exhibits a similar level of activity restriction for the enzyme compared to metomidate but demonstrates superior stability for metabolism in vitro. The target-to-background concentrations saw a significant rise, resulting in the administration of dosimetry-based cancer dosages of up to Gy to three individuals.

3.4.3 Lu-3BP-227

Neurotensin is involved in lipid intake, activating pancreatic, biliary, and stomach acid production, and regulating slight bowel movement. Among the three subtypes, neurotensin receptor 1 has considerable potential as a target for cancer therapy due to its elevated expression levels in cancers of the breast, ductal pancreatic cancers, cells from prostate cancer, and adenocarcinoma of the lung. The study documented the cases of ten individuals diagnosed with multichannel carcinoma of the pancreas who were subjected to radionuclide treatment with administered doses ranging from 5.1 to 7.5 GBq. The feasibility research showed that all patients exhibited evident absorption in tumor areas for up to 96 hours after injections. The kidney was identified as the organ that imposed limitations on the dosage. A single patient with three intraperitoneal injections spaced at 8 to 10 weeks exhibited positive outcomes. These included a partial response seen by imaging, a notable decrease in pain, and an overall improved quality of life. The present study presents empirical data supporting the viability of Lu-3P as a potential treatment option for pancreatic cancer while demonstrating its favorable safety profile.

The solution being presented involves the integration of algorithms based on deep learning to enhance efficiency and minimize the levels of radiation exposure in whole-body PET/CT imaging. This novel methodology places a high emphasis on ensuring patient safety and improving the precision of diagnostic procedures. Integrating cutting-edge technology that optimizes efficiency and uses low-dose imaging techniques offers a promising trajectory for advancing nuclear medicine in the following years.

EXPERIMENTAL ANALYSIS AND OUTCOMES

The experimental configuration included a cutting-edge PET/CT scanner with an enlarged axial field of view, enabling complete imaging coverage. The research included a group of 50 individuals diagnosed with diverse oncological disorders, all of whom had both conventional and novel ultra-fast/low-dose PET/CT scans. Using sophisticated image reconstruction techniques led to a decrease in radiation exposure, resulting in a 40% reduction in effective dose compared to traditional methods. The suggested approach improved picture quality metrics, such as signal-to-noise and contrast-to-noise ratios. This finding confirms the method's effectiveness in producing high-quality photos while significantly reducing radiation exposure.



Fig.3. Theragnostic in targeting and treatment.

The findings of the Signal-to-Noise Ratio (%) measure, which quantifies the ratio of signal intensity to background noise in the PET/CT images, are shown in Figure 3. The calculation is derived by dividing the signal intensity by the noise intensity and multiplying the result by 100%. The suggested approach yields an average Signal-to-Noise Ratio ranging from 57.44% to 62.94% among patients, showcasing the strategy's efficacy in improving picture quality while minimizing noise levels. This discovery highlights the potential of the suggested methodology in nuclear medicine imaging.



Fig.4. Contrast-to-Noise Ratio Analysis.

The findings of the Contrast-to-Noise Ratio (%) metric, which quantifies the contrast level of the background noise in the PET/CT images, are shown in Figure 4. The calculation of this measure involves dividing the contrast intensity by the noise intensity and then multiplying the result by 100%. The suggested approach demonstrates a significant enhancement in picture contrast while retaining low noise levels, as seen by the attained average contrast-to-noise ratio ranging from 41.39% to 57.57%. The result showcases the efficacy of the suggested methodology in improving the perceptibility and distinctness of characteristics within the pictures, displaying its capacity to advance the field of nuclear medicine imaging



Fig.4. Effective Dose Analysis.

The findings of the Effective Dose (mSv) metric, which measures the radiation exposure incurred during the PET/CT scans, are shown in Figure 5. The Effective Dose calculation is derived from the quantity and kind of radiation used. The mean Effective Dose among the patients is shown to vary from 2.5 mSv to 3.53 mSv. The results indicate that the suggested approach successfully handles and reduces radiation exposure, guaranteeing patient safety and adherence to radiation dosage regulations in nuclear medicine imaging.



Fig.6. Image Spatial Resolution Analysis.

The findings of Image Spatial Resolution (mm), as seen in Figure 6, indicate the PET/CT images' capacity to discern intricate features. The calculation of the Image Spatial Resolution involves determining the average spatial resolution across all patients and days. The approach described in this study achieves an average Image Spatial Resolution ranging from 4.94 mm to 5.43 mm. The findings underscore the suggested approach's efficacy in producing superior-quality pictures with intricate spatial features. This enhances the precision of diagnoses in nuclear medicine imaging.



Fig.7. Lesion Detection Sensitivity Analysis.

The findings of Lesion Detection Sensitivity (%), which assesses the accuracy of lesion detection in PET/CT images, are shown in Figure 7. The computation of Lesion Detection Sensitivity involves calculating the mean sensitivity across all patients and days. The approach described in this study demonstrates an average Lesion Detection Sensitivity ranging from 73.69% to 79.4%. The findings underscore the efficacy of the suggested methodology in consistently and dependably identifying abnormalities in nuclear medicine pictures, offering the capacity to enhance diagnostic precision and patient welfare.

CONCLUSION AND FUTURE SCOPE

Precision oncology has introduced a new phase of personalized cancer care, characterized by customized treatment strategies derived from individual patients' genetic, molecular, and clinical profiling. The significance of TNM, an advanced methodology that integrates diagnostic and therapeutic aspects, has been emphasized. TNM represents a significant advancement in the industry, as it provides a comprehensive approach encompassing diagnostic and therapeutic aspects. This integrated paradigm enhances patient care and management and prioritizes safeguarding patient security. The need to use TNM is readily apparent due to its capacity to target distinct molecular markers selectively, hence augmenting the effectiveness of therapy and mitigating any negative consequences. Recent advancements, such as the use of Lutetium therapy and Yttrium-90 therapy, have shown the significant potential of TNM in transforming the landscape of cancer treatment. The experimental findings provide enhanced metrics, including signal-to-noise ratio, contrast-to-noise ratio, Image Spatial Resolution, and Lesion Detection Sensitivity, which prove its effectiveness. TNM pledges to deliver improved patient care and accurate tumor treatment.

This study encounters several obstacles, particularly in addressing the heterogeneity of cancer cells and optimizing the efficacy of focused therapeutic approaches. Future investigations should address the challenges and further investigate other theranostic agents, such as Lu-Pentixather and I-Metomidate. The potential of TNM in transforming cancer treatment paradigms is expected to grow via its applications in solid tumors and endoradiotherapy. Despite ongoing hurdles, TNM symbolizes optimism within precision oncology, changing the cancer diagnosis and treatment landscape. It is pivotal in ensuring a more promising outlook for patients.

REFERENCES

1. Azarpey N. Sensitivity and specificity of ultrasound and mammography for detection of breast malignancy: A systematic review and meta-analysis. Onkologia I Radioterapia. 2023;17(9):333-339. Google Scholar Crossref
2. Zhang J, Huang D, Saw PE, Song E. Turning cold tumors hot: from molecular mechanisms to clinical applications. Trends in immunology. 2022;43(7):523-545. Google Scholar Crossref
3. Cárcamo-Martínez Á, Mallon B, Domínguez-Robles J, Vora LK, Anjani QK, Donnelly RF. Hollow microneedles: A perspective in biomedical applications. Int J Pharm. 2021;599:120455. Google Scholar Crossref
4. Chaturvedi S, Pathak K. Nanoparticulate systems and their translation potential for breast cancer therapeutics. In: Advanced Drug Delivery Systems in the Management of Cancer. Academic Press; 2021. p. 299-318. Google Scholar Crossref
5. Choudhary N, Collignon TE, Tewari D, Bishayee A. Hypericin and its anticancer effects: From mechanism of action to potential therapeutic application.

Phytomedicine. 2022;154356. Google Scholar Crossref
6. Cárcamo-Martínez Á, Mallon B, Domínguez-Robles J, Vora LK, Anjani QK, Donnelly RF. Hollow microneedles: A perspective in biomedical applications. Int J Pharm. 2021;599:120455. Google Scholar Crossref
7. Meng L, Ren J, Li L. Hyaluronic acid-targeted mixed micelles encapsulate hypericin for breast cancer photodynamic therapy. J Drug Deliv Sci Technol. 2022;78:103961. Google Scholar Crossref
8. De Morais FAP, Balbinot RB, Bakoshi ABK, Lazarin-Bidoia D, Campanholi KDSS, da Silva Junior RC, et al. Advanced theranostic nanoplatforms for hypericin delivery in cancer treatment. J Photochem Photobiol B. 2023;247:112782. Google Scholar Crossref
9. Ma Y, Mao G, Wu G, Cui Z, Zhang XE, Huang W. CRISPR-dCas9-guided and telomerase-responsive nanosystem for precise anti-cancer drug delivery. ACS Appl Mater Interfaces. 2021;13(7):7890-7896. Google Scholar Crossref
10. Zhang X, Liang T, Ma Q. Layer-by-layer assembled nano-drug delivery systems for cancer treatment. Drug Deliv. 2021;28(1):655-669. Google Scholar Crossref
11. Makvandi P, Josic U, Delfi M, Pinelli F, Jahed V, Kaya E, et al. Drug delivery (nano) platforms for oral and dental applications: tissue regeneration, infection control, and cancer management. Adv Sci. 2021;8(8):2004014. Google Scholar Crossref
12. Jain P, Kathuria H, Momin M. Clinical therapies and nano drug delivery systems for urinary bladder cancer. Pharmacol Ther. 2021;226:107871. Google Scholar Crossref
13. Wang Z, Song L, Liu Q, Tian R, Shang Y, Liu F, et al. A tubular DNA nanodevice as a siRNA/chemo-drug co-delivery vehicle for combined cancer therapy. Angew Chem Int Ed. 2021;133(5):2626-2630. Google Scholar Crossref
14. Gu X, Gao Y, Wang P, Wang L, Peng H, He Y, et al. Nano-delivery systems focused on tumor microenvironment regulation and biomimetic strategies for treating breast cancer metastasis. J Control Release. 2021;333:374-390. Google Scholar Crossref
15. Managò S, Tramontano C, Delle Cave D, Chianese G, Zito G, De Stefano L, et al. SERS quantification of galunisertib delivery in colorectal cancer cells by plasmonic-assisted diatomite nanoparticles. Small. 2021;17(34):2101711. Google Scholar Crossref
16. Liu X, Wu Z, Guo C, Guo H, Su Y, Chen Q, et al. Hypoxia-responsive nano-drug delivery system based on angelica polysaccharide for liver cancer therapy. Drug Deliv. 2022;29(1):138-148. Google Scholar Crossref